- Home
- RXRX vs HRMY Comparison
RXRX vs HRMY Comparison
Compare RXRX & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- HRMY
- Stock Information
- Founded
- RXRX 2013
- HRMY 2017
- Country
- RXRX United States
- HRMY United States
- Employees
- RXRX N/A
- HRMY N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- RXRX Health Care
- HRMY Health Care
- Exchange
- RXRX Nasdaq
- HRMY Nasdaq
- Market Cap
- RXRX 2.6B
- HRMY 1.9B
- IPO Year
- RXRX 2021
- HRMY 2020
- Fundamental
- Price
- RXRX $7.21
- HRMY $34.83
- Analyst Decision
- RXRX Buy
- HRMY Buy
- Analyst Count
- RXRX 5
- HRMY 10
- Target Price
- RXRX $9.25
- HRMY $49.80
- AVG Volume (30 Days)
- RXRX 16.7M
- HRMY 539.5K
- Earning Date
- RXRX 02-25-2025
- HRMY 02-20-2025
- Dividend Yield
- RXRX N/A
- HRMY N/A
- EPS Growth
- RXRX N/A
- HRMY N/A
- EPS
- RXRX N/A
- HRMY 2.11
- Revenue
- RXRX $65,184,000.00
- HRMY $681,879,000.00
- Revenue This Year
- RXRX $60.17
- HRMY $24.83
- Revenue Next Year
- RXRX $19.88
- HRMY $18.66
- P/E Ratio
- RXRX N/A
- HRMY $16.53
- Revenue Growth
- RXRX 37.64
- HRMY 25.83
- 52 Week Low
- RXRX $5.60
- HRMY $28.14
- 52 Week High
- RXRX $15.74
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- RXRX 52.64
- HRMY 55.30
- Support Level
- RXRX $6.65
- HRMY $33.36
- Resistance Level
- RXRX $7.86
- HRMY $34.96
- Average True Range (ATR)
- RXRX 0.64
- HRMY 1.19
- MACD
- RXRX -0.00
- HRMY 0.16
- Stochastic Oscillator
- RXRX 66.32
- HRMY 81.62
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.